Unusual codon 69 insertions: Influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibility

Journal of Clinical Virology

Volumn 29, Issue 1, 2004, Pages 27-32

  Bulgheroni, Elisabetta ^a   Croce, Francesco ^a   Citterio, Paola ^a   Viganò, Ottavia ^a   Visonà, Raffaella ^b,c   Sala, Eugenio ^b   Galli, Massimo ^a   Rusconi, Stefano ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SANT ANNA HOSPITAL   (Italy)

^c Divisione di Malattie Infettive   (Italy)

Author keywords

Codon 69; Drug resistance; Human immunodeficiency virus 1 (HIV 1); Reverse transcriptase

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; CASE REPORT; CODON; CONTROLLED STUDY; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0346850740     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(03)00082-9     Document Type: Article

References (34)

1. Boden D., Markowitz M. Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. 42:1998;2775-2783.
2. Bonfanti P., Faggion I., La Seta Catamancio S., Violin M., Balotta C., Rusconi S. Response to antiretroviral therapy in a patient with an uncommon codon 69 insertion in the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 44:2000;1767-1768.
3. Briones C., Mas A., Gomez-Mariano G., et al. Dynamics of dominance of dipeptide insertion in reverse transcriptase of HIV-1 from patients subjected to prolonged therapy. Virus Res. 66:2000;13-26.
4. Chou T.-C., Talalay P. Quantitative analysis of dose effect relationships: the combined effect of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:1984;27-55.
5. D'Aquila R.T., Johnson V.A., Welles S.L., et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann. Intern. Med. 122:1995;401-408.
6. de Jong J.J., Goudsmit J., Lukashov V.V., et al. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS. 13:1999;75-80.
7. De Pasquale M.P., Murphy R., Kuritzkes D., et al. Resistance during early virological rebound on amprenavir plus zidovudine plus lamivudine triple therapy or amprenavir monotherapy in ACTG protocol 347. Antiviral Ther. 3:(Suppl. 1):1998;50-51.
8. Drusano G.L., Bilello J.A., Stein D.S., et al. Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic and pharmacologic variables. J. Infect. Dis. 178:1998;360-367.
9. Dulbecco R. Endpoint methods - measurements of the infectious titer of a viral sample. Dulbecco R., Ginsberg H.S. Virology. 1988;22-25 J.P. Lippincott, Philadelphia.
10. Fitzgibbon J.E., Howell R.M., Haberzettl C.A., Sperber S.J., Gocke D.J., Dubin D.T. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxyxytidine. Antimicrob. Agents Chemother. 36:1992;153-157.
11. Hammer S.M., Squires K.E., Hughes M.D., et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiciency virus infection and CD4 cell counts of 200 per cubic milliliter or less. AIDS Clinical Trials Group 320 Study Team. New Engl. J. Med. 337:1997;725-733.
12. Havlir D.V., Petropoulos C.J., Hellmann N.S., Whitcomb J.M., Richman D.D. &The ACTG 347. Evolution of drug resistance associated with loss of viral suppression in patients treated with indinavir, lamivudine and zidovudine. Antiviral Ther. 3:(Suppl. 1):1998;52-53.
13. Hogg R.S., Heath K.V., Yip B., et al. Improved survival among HIV-infevted individuals following initiation of antiretroviral therapy. J. Am. Med. Assoc. 279:1998;450-454.
14. Imamichi T., Berg S.C., Imamichi H., et al. Relative replication fitness of a high-level 3′-azido-3′-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr→Gly) at codon 69. J. Virol. 74:2000;10958-10964.
15. Johnson V.A., Barlow M.A., Merrill D.P., Chou T.-C., Hirsch M.S. Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4 and recombinant interferon-alpha A. J. Infect. Dis. 161:1990;1059-1067.
16. Johnson V.A., Merrill D.P., Videler J., et al. Two-drug combinations of zidovudine and didanosine, and recombinant interferon-a inhibit replication of zidovudine resistant human immunodeficiency virus type 1 synergistically in vitro. J. Infect. Dis. 164:1991;646-655.
17. Kellam P., Boucher C.A.B., Larder B.A. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J. Gen. Virol. 75:1994;341-351.
18. Kosalaraksa P., Kavlick M.F., Maroun V., Le R., Mitsuya H. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro comparative HIV-1 replication assay. J. Virol. 73:1999;5356-5363.
19. Larder B.A., Bloor S., Kemp S.D., et al. A family of insertion mutations between codons 67 and 70 of human imuunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob. Agents Chemother. 43:1999;1961-1967.
20. Mahalingam B., Louis J.L., Reed C.C., et al. Structural and kinetic analysis of drug resistance of HIV-1 protease. Eur. J. Biochem. 263:1999;238-245.
21. Masquelier B., Race E., Tamalet C., et al. Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors. Antimicrob. Agents Chemother. 45:2001;1836-1842.
22. Merrill D.P., Moonis M., Chou T.-C., Hirsch M.S. Lamivudine (3TC™) or stavudine (d4T) in two- and three-drug combinations against HIV-1 replication in vitro. J. Infect. Dis. 137:1996;355-364.
23. Najera I., Holguin A., Quiñones-Mateu M.E., et al. pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J. Virol. 69:1995;23-31.
24. Quiñones-Mateu M.E., Tadele M., Parera M., et al. Insertions in the reverse transcriptase iuncrease both resistance and viral fitness in a human immunodeficiency virus type 1 isolate harbouring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation. J. Virol. 76:2002;10546-10552.
25. Richman D.D. Drug resistance and its implications in the management of HIV infection. Antiviral Ther. 2:(Suppl. 4):1997;41-58.
26. Roberts J.D., Bebenek K., Kunkel T.A. The accuracy of reverse transcriptase from HIV-1. Science. 242:1988;1171-1173.
27. Rusconi S., De Pasquale M.P., Milazzo L., et al. Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1 infected patients in an ongoing open label trial. Antiviral Ther. 2:1997;41-48.
28. Rusconi S., De Pasquale M.P., Milazzo L., et al. Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant human immunodefiency virus type 1 (HIV-1) isolate after discontinuation of in vitro lamivudine drug pressure. Antiviral Ther. 3:1998;203-207.
29. Shafer R.W., Winters M.A., Iversen A.K.N., Merigan T.C. Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 40:1996;2887-2890.
30. Tamalet C., Lafeuillade A., Fantini J., Poggi C., Yahi N. Quantification of HIV-1 viral load in lymphoid and blood cells: assessment during four-drug combination therapy. AIDS. 11:1997;895-901.
31. Tamalet C., Yahi N., Tourres C., et al. Multidrug resistance genotypes (insertions in β3-β4 finger subdomain and MDR mutations) of HIV-1 reverse transcriptase from extensively treated patients: incidence and association with other resistance mutantions. Virology. 270:2000;310-316.
32. Tisdale M., Alnadaf T., Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob. Agents Chemother. 41:1997;1094-1098.
33. Winters M.A., Schapiro J.M., Lawrence J., Merigan T.C. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment. J. Virol. 72:1998;5303-5306.
34. Winters M.A., Cooley K.L., Girard Y.A., et al. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J. Clin. Invest. 102:1998;1769-1775.